Cash Equivalents - GlaxoSmithKline PLC (NYSE:GSK) - Alpha Spread
G

GlaxoSmithKline PLC
NYSE:GSK

Watchlist Manager
GlaxoSmithKline PLC
NYSE:GSK
Watchlist
Price: 38.82 USD 1.17% Market Closed
Market Cap: 79.2B USD
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

GlaxoSmithKline PLC
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GlaxoSmithKline PLC
Cash Equivalents Peer Comparison

Comparables:
A
AZN
INDV
HIK
AGY
DPH

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
G
GlaxoSmithKline PLC
NYSE:GSK
Cash Equivalents
ÂŁ3B
CAGR 3-Years
-5%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
A
AstraZeneca PLC
NASDAQ:AZN
Cash Equivalents
$6.9B
CAGR 3-Years
-24%
CAGR 5-Years
5%
CAGR 10-Years
3%
Indivior PLC
LSE:INDV
Cash Equivalents
$302m
CAGR 3-Years
-33%
CAGR 5-Years
-21%
CAGR 10-Years
39%
Hikma Pharmaceuticals PLC
LSE:HIK
Cash Equivalents
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Allergy Therapeutics PLC
LSE:AGY
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is GlaxoSmithKline PLC's Cash Equivalents?
Cash Equivalents
3B GBP

Based on the financial report for Jun 30, 2024, GlaxoSmithKline PLC's Cash Equivalents amounts to 3B GBP.

What is GlaxoSmithKline PLC's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-1%

Over the last year, the Cash Equivalents growth was -6%. The average annual Cash Equivalents growth rates for GlaxoSmithKline PLC have been -5% over the past three years , -6% over the past five years , and -1% over the past ten years .

Back to Top